Search results (68)
« Back to NewsTravels with Vignesh
9 February 2021
Vignesh Murugesan, a Postdoctoral Researcher in Department of Physiology, Anatomy & Genetics (DPAG), describes how he found his way from the large metropolitan town of Chennai in India to studying regenerative medicine here in Oxford, via an 8 year stint in Sweden.
Pawel Swietach becomes Professor Pawel Swietach
30 October 2020
Congratulations are in order to Pawel Swietach on his conferral of the title of full Professor. Research in the Swietach Lab is driven by an interest in how biological processes are affected by chemical acidity.
MRC Senior Non-Clinical Fellowship awarded to Samira Lakhal-Littleton
27 October 2020
Congratulations are in order for Associate Professor Samira Lakhal-Littleton, who has been awarded a Senior Non-Clinical Fellowship by the Medical Research Council to further her lab's work exploring the implications of the cardiac hepcidin/ferroportin axis for the management of iron deficiency in heart failure.
Paul Riley appointed Director of Oxford’s Institute of Developmental and Regenerative Medicine
11 October 2020
Professor Paul Riley will lead the scientific vision of the first institute of its kind in the world to physically merge the disciplines of developmental biology and regenerative medicine in a common goal to treat some of the world’s most prolific diseases.
CCRF partners with British Society of Echocardiography
4 September 2020
The partnership will produce the first ever British Society of Echocardiography National review of Stress Echocardiography Practice (BSE N-STEP).
Recharging the battery of the diabetic heart
4 September 2020
A new paper from the Heather and Tyler groups has uncovered the mechanism responsible for reduced energy in the hearts of patients with type 2 diabetes and revealed a new therapeutic strategy to reverse the energy deficit.
About 5000 heart attack sufferers in England missed out on hospital treatment due to the pandemic
15 July 2020
The number of admissions to hospital with heart attacks fell by 35% by the end of March.
HCQ with antibiotics to treat COVID-19 could be dangerous for the heart
26 May 2020
DPAG researchers have collaborated on an international study that demonstrates a detailed mechanistic understanding of how the anti-malaria drug, Hydroxychloroquine, combined with antibiotics, can cause adverse cardiac side-effects in COVID-19 patients. This gives weight to US Federal advice against using this combined treatment.
Heart scarring run by Runx1 gene
27 April 2020
New collaborative research from the Mommersteeg Group and MRC WIMM researchers shows that a protein called Runx1 plays a significant role in the formation of the cardiac scar that forms after the heart is injured, a scar that is known to inhibit heart regeneration. In the zebrafish, a freshwater fish known to be able to fully regenerate its heart after damage, they show that the absence of Runx1 results in enhanced regeneration. This indicates a potential new therapeutic target for heart repair.
New heart disease drug to be made available to NHS patients through ground-breaking collaboration
14 January 2020
Up to 30,000 lives could be saved over the next decade thanks to a proposed pioneering government collaboration with pharmaceutical company Novartis to tackle heart disease – a leading cause of death in the UK.
New target identified to help prevent dangerous heart rhythms after heart attack
8 January 2020
For many years, we have been using beta-blockers to neutralise a specific stress hormone and prevent dangerous heart rhythms following a heart attack. However, a new study led by Associate Professor Neil Herring and published in the European Heart Journal has uncovered evidence for an additional stress hormone acting as a key trigger for dangerous heart rhythms that is not currently targeted by these drugs.